A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2018
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors TALENT Biotech
- 20 Sep 2018 According to a Kalytera Therapeutics media release, Dr. Moshe Yeshurun, Kalytera's Chief Medical Officer, was the Principal Investigator for the study. The study was conducted conducted at the Institute of Hematology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
- 16 Feb 2017 Results published in a Kalytera Therapeutics media release.
- 03 Feb 2017 New trial record